Today: Today, Juno Therapeutics Inc (JUNO) Rating Decreased to Hold at SunTrust Banks Inc.

Today, Juno Therapeutics Inc (JUNO) Rating Decreased to Hold at SunTrust Banks Inc.

Juno Therapeutics Inc (NASDAQ:JUNO) was downgraded by equities research analysts at SunTrust Banks Inc. from a “buy” rating to a “hold” rating in a report released on Friday. They presently have a $25.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $48.00. SunTrust Banks Inc.’s target price points to a potential upside of 10.82% from the company’s current price.

Several other analysts also recently commented on the stock. BTIG Research started coverage on shares of Juno Therapeutics in a research report on Tuesday, August 30th. They set a “sell” rating and a $23.00 price objective on the stock. Vetr downgraded shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 price objective on the stock. in a research report on Monday, August 22nd. Leerink Swann reissued an “outperform” rating and set a $45.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, September 27th. Zacks Investment Research raised shares of Juno Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 8th. Finally, Maxim Group cut their price objective on shares of Juno Therapeutics from $50.00 to $34.00 and set a “buy” rating on the stock in a research report on Wednesday. Six research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Juno Therapeutics has an average rating of “Buy” and a consensus price target of $41.47.

Shares of Juno Therapeutics (NASDAQ:JUNO) opened at 22.56 on Friday. The company’s market cap is $2.31 billion. Juno Therapeutics has a 52-week low of $19.41 and a 52-week high of $57.82. The stock has a 50 day moving average of $27.75 and a 200 day moving average of $33.02.

Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.05. The firm had revenue of $20.80 million for the quarter, compared to analysts’ expectations of $10.98 million. Juno Therapeutics’s revenue for the quarter was up 1200.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.26) earnings per share. On average, equities research analysts expect that Juno Therapeutics will post ($2.54) EPS for the current year.

In other Juno Therapeutics news, CEO Hans Edgar Bishop sold 84,035 shares of the firm’s stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $30.28, for a total transaction of $2,544,579.80. Following the sale, the chief executive officer now owns 2,518,537 shares in the company, valued at approximately $76,261,300.36. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Robert Azelby sold 12,921 shares of the firm’s stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $24.14, for a total transaction of $311,912.94. Following the sale, the executive vice president now owns 48,640 shares in the company, valued at approximately $1,174,169.60. The disclosure for this sale can be found here.

A number of large investors have recently added to or reduced their stakes in JUNO. BlackRock Group LTD boosted its stake in Juno Therapeutics by 15.3% in the first quarter. BlackRock Group LTD now owns 34,653 shares of the biopharmaceutical company’s stock worth $1,320,000 after buying an additional 4,609 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in Juno Therapeutics by 27.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 60,000 shares of the biopharmaceutical company’s stock worth $2,374,000 after buying an additional 12,800 shares during the last quarter. State Street Corp boosted its stake in Juno Therapeutics by 20.8% in the first quarter. State Street Corp now owns 1,218,468 shares of the biopharmaceutical company’s stock worth $46,412,000 after buying an additional 210,019 shares during the last quarter. Geode Capital Management LLC boosted its stake in Juno Therapeutics by 4.2% in the first quarter. Geode Capital Management LLC now owns 423,661 shares of the biopharmaceutical company’s stock worth $16,137,000 after buying an additional 17,205 shares during the last quarter. Finally, Alps Advisors Inc. purchased a new stake in Juno Therapeutics during the second quarter worth approximately $5,603,000.

About Juno Therapeutics

Related posts

Leave a Comment